Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dimitry Palceski

Procedural Dermatology Winter Park, FL Doctor of Osteopathy

NPI 1265407290 CMS profile 238098

440 W Morse Blvd, Winter Park, FL 32789

Open in the dashboard

General payments

$23,250

943 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dimitry Palceski of Winter Park, FL is reported in the CMS Open Payments database as having received $23,250 across 943 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,205 155
2024 General $3,223 170
2023 General $2,697 146
2022 General $2,387 119
2021 General $2,264 128
2020 General $4,750 92
2019 General $4,724 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dimitry Palceski
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Dimitry Palceski were reported at $3,205. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Dimitry Palceski Procedural Dermatology median Middle half National median
2019 $4,724 $454 $152–$1,260 $163
2020 $4,750 $243 $90–$835 $114
2021 $2,264 $337 $102–$1,128 $132
2022 $2,387 $443 $119–$1,654 $149
2023 $2,697 $583 $137–$1,838 $160
2024 $3,223 $611 $132–$1,835 $164
2025 $3,205 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $4,044 120 payments
  2. AbbVie, Inc. $3,701 232 payments
  3. Biofrontera Inc. $2,999 21 payments
  4. Almirall LLC $1,496 24 payments
  5. Genzyme Corporation $1,088 43 payments
  6. UCB, Inc. $957 44 payments
  7. Mayne Pharma Inc. $849 34 payments
  8. LEO Pharma Inc. $724 35 payments
  9. Regeneron Healthcare Solutions, Inc. $693 28 payments
  10. Janssen Biotech, Inc. $684 48 payments
  11. Other $6,016 314 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,076 931 payments
  2. Consulting Fee $3,250 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 1 payment
  4. Education $402 8 payments
  5. Travel and Lodging $22 1 payment
Products named General payments · program years 2019–2025
  1. XEPI $2,954 19 payments
  2. Ameluz $2,671 5 payments
  3. BF-RhodoLED $2,671 5 payments
  4. SKYRIZI $1,891 122 payments
  5. DUPIXENT $1,728 65 payments
  6. Seysara $1,257 13 payments
  7. RINVOQ $920 46 payments
  8. HUMIRA $751 44 payments
  9. VTAMA $657 43 payments
  10. TREMFYA $593 39 payments
  11. Other $11,419 646 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

233

Median for Dermatology: 534

Drug cost

$101,894

Median for Dermatology: $67,151

Branded share of claims

14.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 17 $98,100
Doxycycline Hyclate Generic 41 $1,491
Clobetasol Propionate Generic 24 $703
Mupirocin Generic 55 $414
Minoxidil Generic 20 $321
Ketoconazole Generic 20 $299
Valacyclovir Valacyclovir Hcl Brand 16 $227
Triamcinolone Acetonide Generic 29 $196
Nystatin Generic 11 $143

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$137,305

Of which drugs: $39,996

Medicare patients

308

Average age 73

Services billed

32,357

171 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 39%
Ischemic heart disease 33%
Diabetes 20%
Cancer 19%
Depression 18%
Chronic kidney disease 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 99 31,200 $39,989

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$477 17 —
SKYRIZI
$323 — —
VTAMA
$245 — —
RINVOQ
$223 — —
Zoryve
$180 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

943 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record